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Human immunodeficiency virus impairs reverse cholesterol 
transport from macrophages
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We demonstrate that HIV-1, via Nef, impairs ATP-binding
cassette transporter A1 (ABCA1)-dependent cholesterol
efflux from human macrophages. At least two mecha-
nisms were involved: first, HIV infection and transfection
with Nef induced post-transcriptional down-regulation of
ABCA1; and second, Nef caused redistribution of ABCA1
to the plasma membrane and inhibited internalization of
apolipoprotein A-I. Binding of Nef to ABCA1 was required
for down-regulation and redistribution of ABCA1. Stimu-
lation of cholesterol efflux from macrophages reduced
infectivity of produced virions, and this effect correlated
with a decreased amount of virion-associated cholesterol.
Therefore, impairment of cholesterol efflux is essential to
viral replication as it ensures proper cholesterol content in
nascent HIV particles. This impairment may be a contrib-
uting factor to atherosclerosis in HIV patients.
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